GlassScriptPhysician profile
Gillian Edwards
NPI 1609544337
$1,326.99
in general payments reported to CMS, 2019-2025
24 companies · $761 in 2025
The $761 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.82 · 2022: $34.71 · 2023: $88.74 · 2024: $422 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.45 |
| Education | $384.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $150.82 | 2021-2025 | Talvey, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $133.61 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $128.48 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $117.46 | 2025 | Jakafi |
| Seagen INC. | $99.00 | 2025 | |
| Daiichi Sankyo INC. | $83.52 | 2025 | Enhertu, Datroway |
| Pfizer INC. | $76.19 | 2024-2025 | |
| Glaxosmithkline, LLC. | $72.75 | 2024-2025 | Arexvy, Jemperli, Zejula |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $65.86 | 2025 | Imfinzi, Calquence |
| Novo Nordisk INC | $53.46 | 2022-2023 | Wegovy |
| Astellas Pharma US INC | $34.64 | 2025 | Xtandi |
| Novartis Pharmaceuticals Corporation | $33.82 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $24.42 | 2024 | Onivyde |
| Karyopharm Therapeutics INC. | $21.15 | 2025 | Xpovio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.90 | 2024 | |
| Eisai INC. | $20.77 | 2024 | |
| Geron Corporation | $18.65 | 2024 | Rytelo |
| Intera Oncology, INC | $18.46 | 2025 | Intera |
| Beigene USA, INC. | $18.21 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $18.21 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2024 | Opdualag |
| Springworks Therapeutics, INC. | $15.74 | 2024 | Ogsiveo |
| Sobi, INC | $14.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.